Figure 6, Kaplan-Meier Estimates of DFS or Nelarabine Versus No Nelarabine — COG AALL0434 - Nelarabine (Atriance)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Nelarabine (Atriance): CADTH Reimbursement Review: Therapeutic area: T-cell acute lymphoblastic leukemia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.

Nelarabine (Atriance): CADTH Reimbursement Review: Therapeutic area: T-cell acute lymphoblastic leukemia [Internet].

Show details

Contents

Kaplan-Meier curves for DFS with nelarabine versus no nelarabine, with the x-axis as time after postinduction randomization in years and the y-axis as the probability of DFS and a follow-up duration of 10 years. The curves overlap initially and start to separate at 6 months with the curve for nelarabine above that for no nelarabine, and again overlap at 7.5 years and remained overlapped until 10 years.

Figure 6Kaplan-Meier Estimates of DFS or Nelarabine Versus No Nelarabine — COG AALL0434

Source: Dunsmore et al. (2020).¹⁵ Reprinted from Dunsmore KP, Winter SS, Devidas M, et al., Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia, J Clin Oncol, 38(28):3282 to 3293, https://doi.org/10.1200/JCO.20.00256, Copyright © 2020, by the American Society of Clinical Oncology.

: DFS = disease-free survival.

From: Clinical Review

Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).

Contents

Views

Cite this Page
Nelarabine (Atriance): CADTH Reimbursement Review: Therapeutic area: T-cell acute lymphoblastic leukemia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov. Figure 6, Kaplan-Meier Estimates of DFS or Nelarabine Versus No Nelarabine — COG AALL0434.
PDF version of this title (7.3M)

Other titles in this collection

CADTH Reimbursement Reviews and Recommendations

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

Figure 6, Kaplan-Meier Estimates of DFS or Nelarabine Versus No Nelarabine — COG...
Figure 6, Kaplan-Meier Estimates of DFS or Nelarabine Versus No Nelarabine — COG AALL0434 - Nelarabine (Atriance)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on